Aptima HPV Test
Aptima HPV Test by Hologic Inc., detects HPV types that belong to a high risk group for causing cervical cancer. Aptima targets mRNA oncogenes Ε6/Ε7 of the virus1. Studies have shown that a test which targets these areas of the virus accurately identify whether there is a risk the infection evolves to cancer 2,3.
Aptima HPV test has been approved by the FDA USA in 2011 for detecting 14 types of high risk HPV and for identifying types 16, 18/45 4.
1 Aptima® HPV Assay package insert #503789 Rev A 2013.
2 Tinelli A, et al. Curr Pharm Biotechnol. 2009 Dec;10(8):767-71
3 Cuschieri K, et al. J Med Virol. 2004 May;73(1):65-70
4 Department of Health & Human Services, FDA, P100042, APTIMA HPV Assay
CLART HPV Products
CLART HPV test series detects and at the same time identifies HPV types that are of high, low and medium risk groups. All types are detected in a single trial.
The classification is determined by the innate ability of those viruses to cause cervical cancer or other cancer types (pharyngeal, etc.).
HPV identification makes monitoring women possible, as well as assessing those vaccinated, and it is also useful for post treatment follow-ups.READ MORE
Viroactiv HPV test
Viroactiv HPV test detects HPV L1 capsid protein and accurately determines whether a morphology lesion in a woman’s Pap Test may lead to cancer or not.
L1 protein expression is directly associated to precancerous lesions’ evolution to cervical cancer.
The test can be applied to all the cases of Pap test where the cytologist diagnoses ASCUS, AGUS, LSIL, HSIL type morphologic lesions as a prognosis of their evolution.
1. Correlation of Immunochemical Detection of HPV L1 Capsid Protein in Pap Smears with Regression of High-Risk HPV Positive Mild/Moderate Dysplasia, H. Griesser, U.Schenck, Analytical and Quantitative Cytology and Histology, Oct 2004
2. Immunocytochemical Detection of Human Papillomavirus High Risk Type L1 Capsid Proteins in LSIL and HSIL As compared with Detection of HPV L1 DNA, P.Melsheimer, Acta Cytologica, 2003
The information referred to for general information and informing the public and in any case can not replace a doctor or other suitably qualified health professional. The responsibility of the media carries by ENORASIS SA